Depot shot for pain in women with sickle cell disease
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests if a hormone shot (depot medroxyprogesterone acetate) can help reduce pain episodes in women with sickle cell disease. It aims to see if the shot improves pain and markers of inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Women aged 18 to 50 years old.
- Diagnosed with sickle cell disease (types SS, SC, or sickle beta zero/plus thalassemia).
- Had at least 1 painful crisis per month on average in the last 6 months.
- Had 1 to 10 hospital or clinic visits for pain in the past year.
- Not currently using hormonal birth control; must stop all hormonal birth control for at least 1 month before starting the study (or 4 months if you recently had the depot shot).
- Regular menstrual cycles (21 to 35 days long) when not on hormonal birth control.
- Stable doses of sickle cell medications (like hydroxyurea) for at least 6 months.
- No history of blood clots, stroke, or chronic inflammatory conditions like lupus.
- Not currently using crizanlizumab, voxelotor, or chronic blood transfusions.
- Not pregnant or breastfeeding, and no pregnancy in the last 6 months.
- No polycystic ovary syndrome or irregular periods.
- Blood pressure below 160/100 at the screening visit.
- Access to a device with text messaging and able to read English.
- Willing to follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a low-dose of ketamine (a pain medicine) can help children and young adults with sickle cell disease who are in a pain crisis. It aims to provide better pain relief while avoiding some side effects of standard painkillers.
This trial tests if a low dose of ketamine can help relieve pain for people with sickle cell disease who come to the emergency room with a pain crisis. It aims to find a better way to manage pain during these episodes.
This trial tests if adding lidocaine to standard pain treatment can reduce the amount of morphine or oxycodone needed for a severe pain crisis or acute chest syndrome in sickle cell disease. It is for adults in the ICU who have already started opioid treatment within the last 72 hours.
This study tests an experimental pill called etavopivat for people with sickle cell disease who have had some pain crises in the past year. The goal is to see if it reduces these crisis episodes.
This early-phase study tests a new drug (BMS-986470) for people with sickle cell disease who have frequent pain crises. The goal is to see if it can safely reduce crises. It includes a small group of healthy volunteers as well.
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
Hear when a new Vaso-Occlusive Pain Episode in Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.